Stoichiometric and irreversible cysteine-selective protein modification using carbonylacrylic reagents (1)
Barbara Bernardim, Pedro M.S.D. Cal, Maria J. Matos, Bruno L. Oliveira, Nuria Martínez-Sáez, Inês S. Albuquerque, Elizabeth Perkins, Francisco Corzana, Antonio C.B. Burtoloso, Gonzalo Jiménez-Osés & Gonçalo J.L. Bernardes
Nature Communications. 2016 October 26; 7:13128. doi:10.1038/ncomms13128. PMC. WEB 19 Dec. 2016
Pub Type: Data exemplification VELTIS
"The scope of method was then studied on different proteins (Fig. 3a) including an engineered variant of the C2A domain of Synaptotagmin-I (C2Am), which is another apoptosis imaging agent, as well as a recombinant human albumin—Recombumin (Albumedix Ltd), which has been used for example in drug-delivery applications."